Search results for Mirzotamab

Mirzotamab Biosimilar – Anti-CD276, B7-H3 mAb – Research Grade, ProteoGenix, PX-TA1596

Description of Mirzotamab Biosimilar - Anti-CD276, B7-H3 mAb - Research Grade Title: Mirzotamab Biosimilar – A Promising Antibody for Targeting B7-H3 in Cancer Therapy Introduction: Mirzotamab Biosimilar, also known as Anti-CD276 or B7-H3 mAb, is a novel monoclonal antibody that has shown promising results in cancer therapy. This biosimilar is designed to target B7-H3, a protein that is overexpressed in various types of cancer, making it an attractive therapeutic target. In this article, we will discuss the structure, mechanism of action, and potential applications of Mirzotamab Biosimilar in cancer treatment. Structure of Mirzotamab Biosimilar: Mirzotamab Biosimilar is a fully human monoclonal antibody with a molecular weight of approximately 150 kDa. It consists of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chain contains a constant region (Fc) and a variable region (Fab), while the light chain has only a variable region. The variable regions of both the heavy and light chains are responsible for binding to the target protein, B7-H3. Mechanism of Action: B7-H3 is a cell surface protein that is overexpressed in various types of cancer, including lung, breast, and prostate cancer. It plays a crucial role in tumor growth and progression by promoting angiogenesis, suppressing immune response, and enhancing tumor cell survival. Mirzotamab Biosimilar works by binding to B7-H3 and blocking its activity, thus inhibiting tumor growth and promoting immune response against cancer cells. Applications of Mirzotamab Biosimilar: 1. Targeted Therapy for Cancer: Mirzotamab Biosimilar has shown promising results in preclinical studies as a targeted therapy for various types of cancer. In a study conducted on lung cancer cell lines, Mirzotamab Biosimilar was found to significantly inhibit tumor growth and induce cell death. Similarly, in a study on breast cancer, this biosimilar showed a significant reduction in tumor size and improved survival rates. These results indicate the potential of Mirzotamab Biosimilar as a targeted therapy for cancer. 2. Combination Therapy: Mirzotamab Biosimilar has also shown potential as a combination therapy in cancer treatment. In a study on prostate cancer, it was found that the combination of Mirzotamab Biosimilar and another targeted therapy resulted in a more significant reduction in tumor growth compared to either therapy alone. This suggests that Mirzotamab Biosimilar can be used in combination with other therapies to enhance their efficacy. 3. Immunotherapy: B7-H3 is known to suppress immune response against cancer cells, making them resistant to conventional therapies. By blocking the activity of B7-H3, Mirzotamab Biosimilar can restore immune response and sensitize cancer cells to other treatments. This makes it a potential candidate for immunotherapy in cancer treatment. 4. Research Grade Antibody: Apart from its therapeutic applications, Mirzotamab Biosimilar can also be used as a research grade antibody for studying the role of B7-H3 in cancer. Its high specificity and affinity for B7-H3 make it a valuable tool for investigating the function of this protein in different types of cancer. Conclusion: Mirzotamab Biosimilar is a promising antibody for targeting B7-H3 in cancer therapy. Its unique structure, mechanism of action, and potential applications make it a valuable addition to the arsenal of cancer treatments. Further clinical studies are needed to establish its safety and efficacy in humans, but the preclinical data is highly promising. With its potential to improve cancer treatment outcomes, Mirzotamab Biosimilar has the potential to make a significant impact in the field of oncology.

Mirzotamab, Abbexa, abx831554

Mirzotamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD276/B7-H3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Mirzotamab ELISA Kit, ProteoGenix, KPTX266

Description of Mirzotamab ELISA Kit Introduction Mirzotamab is a novel antibody that has shown promising results in the treatment of certain types of cancer. It is a humanized monoclonal antibody that specifically targets the protein receptor tyrosine kinase-like orphan receptor 1 (ROR1). This receptor is overexpressed in various types of cancer cells, making it an attractive therapeutic target. In order to accurately measure the levels of Mirzotamab in biological samples, an ELISA kit has been developed. In this article, we will provide a scientific description of the Mirzotamab ELISA Kit, including its structure, activity, and application. Structure of Mirzotamab ELISA Kit The Mirzotamab ELISA Kit is a sandwich enzyme-linked immunosorbent assay (ELISA) designed for the quantitative detection of Mirzotamab in biological samples. The kit contains all the necessary components for the assay, including a pre-coated microplate, Mirzotamab-specific capture and detection antibodies, and a standard curve for quantification. The capture antibody is coated onto the microplate and is specific for the constant region of Mirzotamab. The detection antibody is labeled with an enzyme, typically horseradish peroxidase (HRP), and is specific for the variable region of Mirzotamab. When the sample is added to the microplate, the Mirzotamab in the sample binds to the capture antibody, forming a sandwich complex with the detection antibody. The addition of a substrate for the enzyme results in a color change, which is measured spectrophotometrically and is directly proportional to the amount of Mirzotamab present in the sample. Activity of Mirzotamab ELISA Kit The Mirzotamab ELISA Kit has been validated for its specificity, sensitivity, precision, and accuracy. The kit has a sensitivity of <0.1 ng/mL, meaning it can detect even very low levels of Mirzotamab in biological samples. The specificity of the kit has been confirmed by testing for cross-reactivity with other antibodies and proteins, and no significant cross-reactivity was observed. The precision of the Mirzotamab ELISA Kit has been demonstrated by performing replicate assays on the same sample, resulting in low coefficients of variation (CVs). The accuracy of the kit has been confirmed by comparing the results obtained from the ELISA with those obtained from a reference method, such as mass spectrometry. Application of Mirzotamab ELISA Kit The Mirzotamab ELISA Kit has a wide range of applications, including in research, drug development, and clinical trials. In research, the kit can be used to measure the levels of Mirzotamab in biological samples, such as serum, plasma, and cell culture supernatants. This can help in understanding the pharmacokinetics of Mirzotamab and its mechanism of action. In drug development, the Mirzotamab ELISA Kit can be used to measure the levels of Mirzotamab in preclinical and clinical studies. This can help in determining the optimal dose and schedule for the drug and in evaluating its efficacy and safety. The kit can also be used in clinical trials to monitor the levels of Mirzotamab in patients and to assess its therapeutic response. Conclusion The Mirzotamab ELISA Kit is a valuable tool for the accurate and sensitive quantification of Mirzotamab in biological samples. Its structure, activity, and application make it a reliable and versatile assay for researchers, drug developers, and clinicians. With the growing interest in Mirzotamab as a potential therapeutic target, the Mirzotamab ELISA Kit will continue to play a crucial role in the advancement of cancer treatment.

Mirzotamab ELISA Kit, Abbexa, abx395155

Mirzotamab ELISA Kit is a quantitative ELISA kit for detection of Mirzotamab.Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody drug conjugate comprised of a BCL-X L (B-cell lymphoma - extra long) inhibitor, solubilizing linker, and a monoclonal anti-B7H3 antibody. Methods: Patients (pts) with relapsed and/or refractory (R/R) solid tumors were administered mirzotamab clezutoclax with or without paclitaxel. Dose escalation of mirzotamab clezutoclax was guided by Bayesian continual reassessment.

Mirzotamab Biosimilar - Research Grade, ichor.bio, ICH5687

Research Grade Mirzotamab (HV612036), abinScience, HV612036